Cargando…
High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule.
The optimal use of mitoxantrone (NOV) in the high-dose range requires elucidation of its maximum tolerated dose with peripheral blood progenitor cell (PBPC) support and the time interval needed between drug administration and PBPC reinfusion in order to avoid graft toxicity. The aims of this study w...
Autores principales: | Ballestrero, A., Ferrando, F., Garuti, A., Basta, P., Gonella, R., Esposito, M., Vannozzi, M. O., Sorice, G., Friedman, D., Puglisi, M., Brema, F., Mela, G. S., Sessarego, M., Patrone, F. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228044/ https://www.ncbi.nlm.nih.gov/pubmed/9310249 |
Ejemplares similares
-
Effect of different cytokines on mammaglobin and maspin gene expression in normal leukocytes: possible relevance to the assays for the detection of micrometastatic breast cancer
por: Ballestrero, A, et al.
Publicado: (2005) -
Vitamin C Effect on Mitoxantrone-Induced Cytotoxicity in Human Breast Cancer Cell Lines
por: Guerriero, Eliana, et al.
Publicado: (2014) -
Low-dosage metronomic chemotherapy and angiogenesis: topoisomerase inhibitors irinotecan and mitoxantrone stimulate VEGF-A-mediated angiogenesis
por: ALBERTSSON, PER, et al.
Publicado: (2012) -
Evaluation of Cyclophosphamide Dosage Schedules in Breast Cancer
por: Stoll, B. A.
Publicado: (1970) -
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
por: Vukovic, V., et al.
Publicado: (1997)